

4 December 2020



ASX Announcement

Company Announcements Platform

Cleansing Notice under Section 708A(5)(e) of the Corporations Act

MELBOURNE, 4 December 2020, Anantara Lifesciences Limited (ASX: ANR) ('**Anatara**' or '**Company**') has issued 3,666,666 ordinary shares in the issued capital of the Company pursuant to sophisticated and professional investor, as approved by Shareholders at the Company's Annual General Meeting on 26 November 2020 (**Tranche 2 Placement Shares**).

For the purposes of section 708A(6) of the *Corporations Act 2001* (Cth)(**Act**), the Company hereby notifies the ASX that:

- (a) the Company issued the shares without disclosure to investors under Part 6D.2 of the Act;
- (b) this notice is given under section 708A(5)(e) of the Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company;
 - (ii) section 674 of the Act; and
- (d) as at the date of this notice, there is no other information that is excluded information of the type referred to in sections 708A(7) and 708A(8) of the Act which is required to be disclosed pursuant to section 708A(6)(e) of the Act.

This announcement was approved by the full Board of the Company.

Yours faithfully

A handwritten signature in black ink, appearing to read "Stephen Denaro", is written over a light grey horizontal line.

Stephen Denaro
Company Secretary
Anatara Lifesciences Limited



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com

About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.